Amendments to the Specification

Please replace the paragraph at page 5, lines 7 through 11 with the following amended paragraph:

BRIEF DESCRIPTION OF THE FIGURES

The Figure represents the catalytic iron content (nmol/mg urinary creatinine) in urine obtained from humans with no kidney disease (control), with diabetic microalbuminuria (DM Micro), diabetic (DM) proteinuria, glomerulonephritis ~~(GM)~~ (GN) and ischemic nephrophathy.

Please replace the paragraph at page 8, lines 7 through 9 with the following amended paragraph:

~~O_2~~ O_2^- + Fe^{3+} → O_2 + Fe^{2+}

Fe^{2+} + H_2O_2 → Fe^{3+} + OH• + OH^-

~~O_2~~ O_2^- + H_2O_2 → O_2 + OH• + OH^-

Please replace the paragraph at page 17, lines 8 through 17 with the following amended paragraph:

The phrase "reducing the severity" (also referred to herein as a reduction in the severity) when referring to a progressive kidney disease means any diminution, amelioration or decrease in progressive damage to the kidney that compromises the function of the kidney. Well- recognized indices to assess function of the kidney can be employed to determine a reduction in the severity of the kidney disease. These indices can include, for example, a reduction in protein content in urine, a reduction in blood urea nitrogen, a reduction in serum or plasma creatinine, ~~a decline~~ an increase in glomerular filtration rate, a delay in the onset of end-stage renal disease, or any combination thereof, compared to a sample obtained from the human prior to administering the iron chelator, or a control sample.

Please replace the Table 1 at page 36, lines 1 through 46 with the following amended Table 1:

Table 1: Urinary Catalytic Iron In Patients with Progressive Kidney Disease

Age/Sex/Race			Diagnosis	24 hr prot (mg/24 hrs)	Serum Cr (mg/dl)	CrCl (ml/min)	Catalytic Iron (Nmol/mg creatinine)
20	F	W	Membranous	8900	1.1	120.0	33.4
23	M	W	Membranous	4200	2.3		22.3
50	F	B	SLE	5000	1.9	57.0	90.7
51	F	B	SLE	5000	1.4		9.1
64	M	W	SLE	3700	0.9		11.0
45	F	W	SLE	3700	0.6		69.0
38	F	B	SLE	6843	4.4		70.0
38	F	B	FSGS	5000	2.6		52.7
7	M	W	FSGS	20790	2.1	30.6	48.6
15	F	B	FSGS	2360	0.8	110.2	43.7
14	F	B	FSGS	16350	2.3	38.6	17.3
32	M	B	FSGS	300	2.2		20.1
40	F	B	FSGS	5200	1.7		61.6
40	M	W	FSGS		2.1		28.0
40	M	B	FSGS	15730	3.3	20.0	118.0
11	F	W	HSP	11120	0.6	139.3	26.1
<1	M	W	HUS		0.7		84.2
16	M	B	IgA	830	1.6	58.4	19.1
<1	M	B	MPGN	2104	0.5	75.0	66.8
54	M		MPGN		3.8		43.0
40	M	W	MPGN	16260			106.0
65	F	W	Creacentic		5.9		5.4
Mean							48
SEM							7
Number							22
P							<0.0001
				Ischemic Nephropathy			
45	F	W	Isch Neph		1.8		92.0
80	F	W	Isch Neph		2.0		96.0
Mean							94.0
SEM							2.0
Number							2
P							<0.01

SLE: Systemic Lupus Erythematosus; FSGS=Focal Segmental Glomerulosclerosis;
HSP=Henoch-Schonlein Purpura; HUS=Hemolytic Uremic Syndrome;
MPGN=Membranoproliferative Glomerulonephritis; Isch Neph=Ischemic Nephropathy
SLE, ~~HPS~~ HSP, HUS and Ischemic Nephropathy are secondary causes of renal disease.
P compared to control value of 8.1 ± 1.4, n=23, using unpaired t test

Isch Neph=Ischemic Nephropathy
prot=protein
Cr=creatinine
CrCl=creatinine Clearance